Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Neuro-Oncology|January 25, 2017
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastomaJoseph P Antonios, Horacio Soto, Richard G Everson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2014
Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomasSichen Li, Reshmi Chowdhury, Fei Liu, et al.
Journal of Neuro-Oncology|March 7, 2019
SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activationFei Liu, Christopher D Cox, Reshmi Chowdhury, et al.
Molecular Therapy. Nucleic Acids|July 25, 2013
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular VesiclesWalter W Chen, Leonora Balaj, Linda M Liau, et al.
Molecular Cancer Research : MCR|October 21, 2011
Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cellsYue Liu, Fei Ye, Kazunari Yamada, et al.
Journal of Neuro-Oncology|October 22, 2011
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopyWhitney B Pope, Robert M Prins, M Albert Thomas, et al.
Cancer Research|February 27, 2013
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicityKevin J Williams, Joseph P Argus, Yue Zhu, et al.
Science Signaling|December 17, 2009
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapyDeliang Guo, Robert M Prins, Julie Dang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2007
Assessing the significance of chromosomal aberrations in cancer: methodology and application to gliomaRameen Beroukhim, Gad Getz, Leia Nghiemphu, et al.
Cancer Discovery|November 8, 2011
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathwayDeliang Guo, Felicia Reinitz, Mary Youssef, et al.
Pageof 4